With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
Merck is a mature cash-generator currently heavily reliant on its blockbuster oncology drug Keytruda and the Gardasil vaccine franchise. While near-term cash flows and dividend safety are robust, the long-term investment thesis hinges on management's ability to successfully commercialize its pipeline of Antibody-Drug Conjugates (ADCs) and leverageLeverageThe proportion of debt in the company's capital structure. Commonly measured as Debt/EBITDA, Debt/Equity, or Net Debt/EBITDA. M&A to offset the massive patent cliff approaching in 2028.
A severe stress test assumes structural earnings decline post-2028 as Keytruda revenues drop, combined with a failure to realize ADC revenueRevenueRevenue is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions. and M&A integration issues, compressing gross margins.
Failure to offset Keytruda LOE through M&A or internal ADC pipeline leaves a massive revenue gap, severely compressing structural margins.
Late-stage clinical failures in the Antibody-Drug Conjugate pipeline erode future growth vectors, stalling the dividend trajectory.
Aggressive regulatory pricing pressures from the IRA compress margins more sharply than modeled, stunting near-term operating cash flows.
| Line item | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|
| Revenue | $59.28B | $60.12B+1.4% | $64.17B+6.7% | $65.01B+1.3% | +3.1% |
| Gross profit | $41.87B | $43.99B | $48.98B | $48.63B | +5.1% |
| Operating income | $18.28B | $2.95B | $20.22B | $22.11B | +6.5% |
| Net income | $14.52B | $365.0M-97.5% | $17.12B+4590.4% | $18.25B+6.6% | +7.9% |
| EPS (diluted) | $5.71 | $0.14 | $6.74 | $7.28 | +8.4% |
| EBITDA | $21.32B | $6.91B | $25.71B | $28.26B | +9.9% |
| R&D | $13.55B | $30.53B | $17.94B | $15.79B | +5.2% |
| SG&A | $10.04B | $10.50B | $10.82B | $10.73B | +2.2% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Unfavorable shifts in gross margin trajectories | Monitor | Deterioration versus the report thesis |
| Management signaling a pause or slowing of dividend growth | Monitor | Deterioration versus the report thesis |
